AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 56 min read$PTGX

Protagonist Therapeutics, Inc (PTGX): Results of Operations and Financial Condition

Protagonist Therapeutics, Inc (PTGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update ICOTYDE™ First Full Quarter of Commercial Sales with Strong Early Adoption Rusfertide NDA under Priority Review for Polycythemia Vera; PDUFA Date in August 2026 Comprehensive Phas

Original reporting
SEC EDGAR 8-K
Published Aug 5, 2026, 8:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$PTGX
Bullish
high confidence
Mentioned
$PTGX
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PTGXBullishMed
01

Why it matters

Traders can reprice probability-weighted outcomes for rusfertide ahead of the August 2026 PDUFA decision, while also monitoring ICOTYDE’s early commercial adoption and the timing of pipeline starts in early 2027.

02

Market read

Primary-source disclosure of a near-term FDA decision timeline (Priority Review, PDUFA in August 2026) plus first full quarter of ICOTYDE commercial sales and updated cash position.

03

What to watch

The filing emphasizes milestone and royalty economics from opt-out and collaboration, but it does not provide detailed guidance or full income statement drivers beyond the reported quarter.

Relevance 7/10Novelty 7/10Timing: today’s SEC 8-K, with August 2026 FDA decision window highlighted

Background

This is Protagonist Therapeutics’ SEC Form 8-K (Item 2.02) reporting Q2 2026 financial results and a corporate update on its commercial product ICOTYDE and late-stage rusfertide NDA review status.

Company-level read

Ticker impact

$PTGXBullishHigh confidence
Context

PTGX reported Q2 2026 results and disclosed rusfertide NDA Priority Review with an August 2026 PDUFA decision plus ICOTYDE first full quarter sales.

Expected impact

Bias to upside volatility into the August 2026 PDUFA date, with additional support from the reported cash balance and new milestone/royalty economics.

Evidence & confidence

The filing is a primary-source 8-K with concrete, time-bound regulatory and commercial milestones (Priority Review, PDUFA in August, first full quarter commercial sales) and quantified financial position (cash $849.5M as of June 30, 2026).

Market effects

Sector

Reinforces investor focus on oral peptide platforms and late-stage hematology and psoriasis assets with near-term FDA catalysts.

Regional

Limited direct regional spillover; primarily US biotech sentiment tied to FDA review timelines.

Global

Takeda and Johnson & Johnson collaboration economics and global commercialization rights can influence broader pharma partnering sentiment.

Counterpoint

What could challenge this read

Commercial ramp for ICOTYDE is early, and the biggest value driver (rusfertide) remains contingent on FDA outcome despite Priority Review.

Key entities

  • company
    Protagonist Therapeutics, Inc.

    Nasdaq-listed biotech reporting Q2 2026 results, ICOTYDE commercial ramp, and rusfertide NDA Priority Review with August 2026 PDUFA.

  • partner
    Takeda Pharmaceutical Company

    Holds exclusive worldwide development and commercialization rights to rusfertide after Protagonist’s opt-out, with milestone and royalty economics described.

  • partner
    Johnson & Johnson

    Received FDA approval for ICOTYDE, triggering a $50M milestone and supporting Protagonist’s collaboration economics.

  • regulator
    FDA

    Completing review of rusfertide NDA under Priority Review with a PDUFA goal date in August 2026.

Read at source← All news

Related articles

AUG 28
$HIMSHighAI 8/10

Hims & Hers (HIMS) CEO Says the FTC Doesn’t Understand His Own Company

Hims & Hers (HIMS) CEO Andrew Dudum defended the company against an FTC lawsuit, citing its revenue growth and subscriber base. Q2 revenue rose 40% YoY to $753M, with a full-year forecast of $3.1B-$3.3B. However, margins fell to 64% from 76%, and free cash flow was negative $68M, raising concerns about profitability and legal risks.

yahoo.com2 min
AUG 28
$ESTCHighAI 9/10

Why Is Elastic (ESTC) Stock Rocketing Higher Today

Elastic (ESTC) shares rose 18.4% after Q2 results beat estimates, with revenue of $478.1M (up 15.1% YoY) and EPS of $0.70. The company raised its full-year revenue forecast to $2.0B and adjusted earnings guidance to $3.33 per share. Subscription revenue was $449M, driven by demand for its search and AI platform.

financialcontent.com2 min
AUG 28
$BEMed

Oracle's Data Center Spending Is Exploding. Here's the Power Stock That Actually Benefits.

Oracle (ORCL) is expanding its cloud and AI infrastructure, partnering with Bloom Energy (BE) for up to 2.8 GW of on-site fuel cell electricity. Bloom reported Q2 revenue of $1.065B, up 166% YoY, and expects full-year revenue of $3.9B-$4.2B. EPS was $0.62, reversing a prior-year loss. Bloom's customers include Oracle, Equinix (EQIX), and Brookfield. The fuel cell market is projected to grow at 20% annually.

yahoo.com2 min
AUG 28
$SMedAI 8/10

SentinelOne (S) Stock Trades Down, Here Is Why

SentinelOne (S) shares fell 8.5% after reporting Q2 revenue of $292M (up 20.6% YoY) and beating estimates, but lowered full-year EPS guidance by 11.4% to $0.31. New large customers slowed to 13, raising concerns. The company raised revenue and operating income forecasts but cited higher share count and FX impacts for the earnings cut.

financialcontent.com2 min